ReviewCurrent oncology reports2026
Emerging Role of Bispecific Antibodies in Precision Medicine, Cancer and Modern Therapeutics.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBi-specific antibodies (bs-Abs) represents a significant leap forward in the field of antibody engineering. As this field continues to advance rapidly and offers a range of molecular designs, production methods, and clinical uses, it is essential to summarize the platforms and technologies that enable the development of bsAbs. The review provides a brief overview, types and functions, current therapeutic uses, limitations and future prospects of bs-Abs with a brief outlook of research needs in this new field of therapeutics. RECENT
findingsBi-specific antibodies (bsAbs) engineering design has evolved from initial scFv-based constructs to over 30 commercial platforms. These platforms encompass IgG-like formats such as knobs-into-holes, DEKK, and ART-Ig, along with non-IgG-like formats like BiTE, DART, and tandem. Clinical improvements have also occurred, with the FDA approving Blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL) and Amivantamab for non-small cell lung cancer. Currently, more than 35 additional candidates are in clinical trials for both solid and hematological cancers. Despite promising outcomes, challenges such as immunogenicity, manufacturing complexity, and target specificity limitations remain, underscoring the need for improved bsAb designs and development strategies. BsAbs constitute an expanding group of next-generation therapies with greater clinical impact. Continued refinement of engineering platforms, coupled with advances in discovery technologies and manufacturing, is accelerating their translation and supporting development of more precise and adaptable therapeutic options.
Indexed as
Identifiers
41758301What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.